Sarah Weber's questions to Ovid Therapeutics (OVID) leadership • Q4 2017
Question
Sarah Weber of Piper Jaffray Companies asked about the blinded safety and tolerability data for OV935 in the dEE trial, the planned number and location of sites for the Fragile X Rocket study, and the company's strategy for its OV101 patent portfolio.
Answer
Executive Matthew During commented that in the dEE trial, the drug has been 'extremely well tolerated' so far, with patients titrating to the target dose. Executive Amit Rakhit added that the Rocket study will primarily use U.S. sites, with some international sites being explored. CEO Jeremy Levin stated that the company feels 'very good' about its patent strategy, which has secured protection for its compounds well into the 2030s.